Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.
Cost restraints can keep patients from accessing life-preserving cancer drugs, according to two recent studies.
A study published January 8, 2018 in JAMA, found that new breast cancer therapies played a larger role in the reduction in breast cancer deaths between 2000 and 2012 than even advances in screening. The analysis found that breast cancer mortality rates had been reduced compared with projected baseline in both 2000 and 2012. Furthermore, the analysis found that the majority of the reduction in both 2000 and 2012 was associated with drug therapy versus improvements in screening.
“Healthcare executives challenged with covering expensive new oncology treatments may question how much these drugs are changing the disease course for patients,” says Jeremy Schafer, PharmD, MBA, senior vice president, director – Payer Access Solutions, Precision for Value. “The study reinforces that, in breast cancer, the right drug in the right patient has meaningful effect in a real-world setting and can bend the survival curve. These findings should encourage healthcare executives to apply cost control programs that permit access to high-value drugs for appropriate patients.
“Applying blanket programs like those with high out-of-pocket costs may reduce both appropriate and inappropriate use, leading to worse outcomes in appropriate patients,” Schafer says.
Another study, published December 20, 2017, in the Journal of Clinical Oncology, show that patients are much more likely to abandon oral cancer agent therapy if their upfront cost is too high. Led by researchers at the Perelman School of Medicine at the University of Pennsylvania, the study tracked 38,000 patients who received an oral oncolytic agent in the period of 2014 to 2015. It found that patient abandonment of drug therapy rose dramatically based on cost share from 10% in patients charged less than $10 to 32% for patients with a cost share of $100 to $500 and to nearly 50% for those with a cost share over $2000. These findings were consistent with others in specialty drugs showing a relationship between patient cost share and prescription abandonment.
“The findings indicate that patients will forgo even crucial cancer treatment if they cannot afford it,” Schafer says. “Healthcare benefits with high out-of-pocket cost may reduce costs but have the potential to do so through prescription avoidance by both appropriate and inappropriate patients. The results were consistent across cancer types, even for treatments that have been proven to be life extending. New cancer treatments are costly, but many have shown significant benefit. In order to address the trends evident in the JAMA article, healthcare executives need to find ways to make high-value agents accessible for appropriate patients.”
Based on the two studies, Schafer offers these seven tips for healthcare executives: